Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

Phase 3

Recruiting

• Conditions: Lower Respiratory Tract Illness
• Interventions: Biological: Placebo; Biological: RSVpreF

• Registration Number: NCT05035212
• Lead Sponsor: Pfizer

Brief Summary

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults:

* At a dose of 120µg.

* In adults 60 years of age and older.

* The duration of the study for each participant will be up to approximately 24 months.

* The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa.

Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)

* Blood samples will be collected for antibody testing.

* The duration of the study for each participant will be up to approximately 18 months.

* The study will be conducted in the United States and Argentina.

Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)

* Blood samples will be collected for antibody testing.

* The duration of the study for each participant will be up to approximately 18 months.

* The study will be conducted in Argentina.

Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years:

* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)

* Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study.

* Blood samples will be collected for antibody testing.

* The duration of the study for each participant will be up to approximately 18 months.

* The study will be conducted in the United States and Canada.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2021-08-20
• Study First Submitted QC: 2021-08-30
• Study Start: 2021-08-31
• Study First Posted: 2021-09-05
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-19
• Last Update Posted: 2024-11-20
• Primary Completion: 2026-06-12
• Study Completion: 2026-06-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 38567

Inclusion Criteria

• Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
• Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

• Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

• Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

• Male or female participants ≥60 years of age.

  • Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  • Female participants must not be of childbearing potential.

Read More

Exclusion Criteria

• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
• Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
• Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 3).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

• Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
• Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.
• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Substudy A

Inclusion Criteria:

• Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
• Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

• Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

• Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

• Male or female participants ≥60 years of age.

  • Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  • Female participants must not be of childbearing potential.

• Participants who received RSVpreF in the efficacy study.

• Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration.

Exclusion Criteria:

• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
• Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
• Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 103).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study

• Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

• Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
• Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy A.

• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
• Participant was confirmed by the sponsor to have previously received the study intervention more than once.

Substudy B

Inclusion Criteria:

• Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, including collection of nasal swabs by themselves and by study staff when indicated.
• Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

• Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

• Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

• Male or female participants ≥60 years of age.

  • Male participants able to father children must agree to use a highly effective method of contraception from the time of informed consent through at least 28 days after study intervention administration.
  • Female participants must not be of childbearing potential. 6. Participants who received RSVpreF in the efficacy study.

• Participants who received RSVpreF in the efficacy study.

• Participants who have a Visit 2 serology sample available for testing from the efficacy study and did not meet exclusion criteria through Visit 4 of the efficacy study.

Exclusion Criteria:

• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
• Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
• Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 203).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study - Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

• Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
• Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy B.

• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
• Participant was confirmed by the sponsor to have previously received the study intervention more than once.
• Participants who completed Vaccination 1 from the efficacy study less than 9 months or greater than 15 months prior to revaccination.

Substudy C

Inclusion Criteria:

• Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, frequent symptom assessment by mobile device application, and other study procedures, when indicated.
• Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Note: Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. Specific criteria for participants with known stable infection with HIV, HCV, or HBV can be found in the protocol.

• Adults who are ambulatory and live in the community, or in assisted living or long-term care residential facilities that provide minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.
• Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
• Male or female participants ≥60 years of age.
• Participants who received RSVpreF in the efficacy study.
• Participants who have a Visit 2 serology sample available for testing from the efficacy study, completed the end-of-Season 2 visit (Visit 5), and did not meet exclusion criteria throughout the efficacy study duration.

Exclusion Criteria:

• Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
• History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
• Serious chronic disorder including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
• Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
• Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Participation in other studies involving an investigational product within 28 days prior to consent and/or through and including the 6-months follow-up visit (Visit 303 or Visit 306).

Note: This criterion does not apply to participants who are participating in a follow-up period for another study involving a study intervention that is an investigational drug or vaccine, if receipt of the last dose was at least 6 months prior to consenting for this study and there is no further dosing anticipated from the previous study during the participant's participation in this study

• Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled in the study until corticosteroid therapy has been discontinued for at least 28 days before study intervention administration. Inhaled/nebulized, intra articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

Note: Participants with COPD or asthma can be enrolled if chronic corticosteroids do not exceed a dose equivalent to 10 mg/day of prednisone.

• Receipt of blood/plasma products or immunoglobulin within 60 days before study intervention administration.
• Previous vaccination with any licensed or investigational RSV vaccine or planned receipt during study participation.

Note: This criterion does not include the receipt of RSVpreF in the efficacy study. Per inclusion criterion #6, receipt of RSVpreF in the efficacy study is required to participate in Substudy C.

• Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
• Participant was confirmed by the sponsor to have previously received the study intervention more than once.
• Prior history of any subtype of Guillain-Barré syndrome of any etiology.
• Current or prior participation in Substudy A or Substudy B.
• Participants who completed Vaccination 1 from the efficacy study less than 32 months or greater than 40 months prior to revaccination.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Efficacy Study: Placebo dose	Placebo	Placebo
SSC: Vaccination of RSVpreF recipients with Placebo	Placebo	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at both the Year 3 and Year 4 vaccination in SSC.
SSB: Vaccination of RSVpreF recipients with Placebo	Placebo	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive Placebo in SSB.
SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 4 revaccination)	RSVpreF	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive placebo at the Year 3 vaccination followed by RSVpreF at the Year 4 vaccination in SSC.
SSC: Vaccination of RSVpreF recipients with RSVpreF (Year 3 revaccination)	RSVpreF	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSC will receive RSVpreF at the Year 3 vaccination followed by placebo at the Year 4 vaccination in SSC.
Efficacy Study: RSVpreF vaccine	RSVpreF	RSVpreF
SSA: Vaccination of RSVpreF recipients with Placebo	Placebo	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive Placebo in SSA.
SSB: Vaccination of RSVpreF recipients with RSVpreF (Year 1 revaccination)	RSVpreF	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSB will receive RSVpreF in SSB.
SSA: Vaccination of RSVpreF recipients with RSVpreF (Year 2 revaccination)	RSVpreF	Participants who originally received RSVpreF in the Efficacy Study and are eligible for SSA will receive RSVpreF in SSA.

Primary Outcome Measures

Name	Time	Method
SSA: Proportion of participants reporting prompted local reactions within 7-days after revaccination	Within 7 days after revaccination	Local reactions included pain at injection site, redness and swelling recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: 2.5 to 5.0 cm, moderate: \> 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily activity
SSA: Proportion of participants reporting prompted systemic events within 7-days after revaccination	Within 7 days after revaccination	Systemic reactions:fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and any systemic event recorded by participants in an e-diary. Fever: greater than equal to (\>=)38.0 degrees (deg) Celsius (C), mild (\>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C), moderate (\>38.9 to 40.0 deg C and \>40.0 deg C), severe (\>38.9 deg C to 40.0 deg C) and grade 4 (\>40.0 deg C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: requires intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h.
SSA: Proportion of participants reporting NDCMC throughout the study	Throughout the study duration (approximately 18 months)	An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects (eg, asthma).
Efficacy Study: Number of first episode of RSV-associated lower respiratory tract illness (LRTI-RSV) in the first RSV season	From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 2 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.; Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 3 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreF	Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSA	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSB: Proportion of participants reporting prompted local reactions within 7-days after revaccination	Within 7 days after revaccination	Local reactions included pain at injection site, redness and swelling recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: 2.5 to 5.0 cm, moderate: \> 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily activity.
SSB: Proportion of participants reporting NDCMC throughout the study	Throughout the study duration (approximately 18 months)	An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects (eg, asthma).
Efficacy Study: Proportion of participants reporting prompted local reactions within 7-days after vaccination	Within 7 days after vaccination	Local reactions included pain at injection site, redness and swelling recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: 2.5 to 5.0 cm, moderate: \> 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily activity
Efficacy Study: Proportion of participants reporting AE within 1-month after vaccination	Within 1 month after vaccination (up to 35 days)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs included both serious and non-serious adverse events.
Efficacy Study: Proportion of participants reporting SAE throughout the study	Throughout the study duration (an average of 30 months)	SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Efficacy Study: Proportion of participants reporting prompted systemic events within 7-days after vaccination	Within 7 days after vaccination	Systemic reactions:fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and any systemic event recorded by participants in an e-diary. Fever: greater than equal to (\>=)38.0 degrees (deg) Celsius (C), mild (\>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C), moderate (\>38.9 to 40.0 deg C and \>40.0 deg C), severe (\>38.9 deg C to 40.0 deg C) and grade 4 (\>40.0 deg C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: requires intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h.
Efficacy Study: Proportion of participants reporting NDCMC throughout the study	Throughout the study duration (an average of 30 months)	An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects (eg, asthma).
SSA: Proportion of participants reporting AE within 1-month after revaccination	Within 1 month after revaccination (up to 35 days)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs included both serious and non-serious adverse events.
SSA: Proportion of participants reporting SAE throughout the study	Throughout the study duration (approximately 18 months)	SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 3)	1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 3)	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean of individual NT ratios (GMIR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 3)	Within 7 days after revaccination	Local reactions included pain at injection site, redness and swelling recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: 2.5 to 5.0 cm, moderate: \> 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily activity.
SSC: Proportion of participants reporting NDCMC after revaccination (Year 4)	Following revaccination and throughout the study duration (approximately 6 months)	An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects (eg, asthma).
SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received 2-dose of RSVpreF	Before revaccination and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSB	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSC: Proportion of participants reporting prompted local reactions within 7-days after revaccination (Year 4)	Within 7 days after revaccination	Local reactions included pain at injection site, redness and swelling recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm and graded as mild: 2.5 to 5.0 cm, moderate: \> 5.0 to 10.0 cm and severe: \>10 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfere with daily activity and severe: prevented daily activity.
SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 4)	Within 1 month after revaccination (up to 35 days)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs included both serious and non-serious adverse events.
SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination	SSB: Proportion of participants reporting prompted systemic events within 7-days after revaccination	Systemic reactions:fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and any systemic event recorded by participants in an e-diary. Fever: greater than equal to (\>=)38.0 degrees (deg) Celsius (C), mild (\>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C), moderate (\>38.9 to 40.0 deg C and \>40.0 deg C), severe (\>38.9 deg C to 40.0 deg C) and grade 4 (\>40.0 deg C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: requires intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h.
SSC: Proportion of participants reporting SAE after revaccination (Year 3)	Following revaccination and throughout the study duration (approximately 18 months)	SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
SSB: Proportion of participants reporting AE within 1-month after revaccination	Within 1 month after revaccination (up to 35 days)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs included both serious and non-serious adverse events.
SSB: Proportion of participants reporting SAE throughout the study	Throughout the study duration (approximately 18 months)	SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 4)	1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSC (Year 4)	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean of individual NT ratios (GMIR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 3)	Within 7 days after revaccination	Systemic reactions:fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and any systemic event recorded by participants in an e-diary. Fever: greater than equal to (\>=)38.0 degrees (deg) Celsius (C), mild (\>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C), moderate (\>38.9 to 40.0 deg C and \>40.0 deg C), severe (\>38.9 deg C to 40.0 deg C) and grade 4 (\>40.0 deg C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: requires intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h.
SSC: Proportion of participants reporting prompted systemic events within 7-days after revaccination (Year 4)	Within 7 days after revaccination	Systemic reactions:fever, fatigue/tiredness, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and any systemic event recorded by participants in an e-diary. Fever: greater than equal to (\>=)38.0 degrees (deg) Celsius (C), mild (\>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C), moderate (\>38.9 to 40.0 deg C and \>40.0 deg C), severe (\>38.9 deg C to 40.0 deg C) and grade 4 (\>40.0 deg C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours(h), moderate: \>2 times in 24h and severe: requires intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h.
SSC: Proportion of participants reporting AE within 1-month after revaccination (Year 3)	Within 1 month after revaccination (up to 35 days)	An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. AEs included both serious and non-serious adverse events.
SSC: Proportion of participants reporting SAE after revaccination (Year 4)	Following revaccination and throughout the study duration (approximately 6 months)	SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
SSC: Proportion of participants reporting NDCMC after revaccination (Year 3)	Following revaccination and throughout the study duration (approximately 18 months)	An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or otherwise long-lasting in its effects (eg, asthma).

Secondary Outcome Measures

Name	Time	Method
Efficacy Study: Number of first episode of RSV-associated ARI (ARI-RSV) in the first RSV season	From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. ARI-RSV is defined as an ARI with at least 1 signs/symptoms lasting more than 1 day, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
Efficacy Study: Number of first episode of RSV-associated severe LRTI (sLRTI-RSV) in the first RSV season	From Day 15 after vaccination until the end of season 1 visit (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. sLRTI-RSV is defined as LRTI-RSV with at least 1 of the conditions: 1)Hospitalization due to LRTI-RSV; 2)New/increased oxygen supplementation; 3)New/increased mechanical ventilation
Efficacy Study: Number of first episode of LRTI-RSV in the second RSV season	During the second RSV season (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 2 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.; Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 3 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
Efficacy Study: Number of first episode of ARI-RSV in the second RSV season	During the second RSV season (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. ARI-RSV is defined as an ARI with at least 1 signs/symptoms lasting more than 1 day, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
Efficacy Study: Number of first episode of sLRTI-RSV in the second RSV season	During the second RSV season (an average of 6 months)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. sLRTI-RSV is defined as LRTI-RSV with at least 1 of the conditions: 1)Hospitalization due to LRTI-RSV; 2)New/increased oxygen supplementation; 3)New/increased mechanical ventilation
Efficacy Study: Number of first episode of sLRTI-RSV across 2 RSV seasons	From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. sLRTI-RSV is defined as LRTI-RSV with at least 1 of the conditions: 1)Hospitalization due to LRTI-RSV; 2)New/increased oxygen supplementation; 3)New/increased mechanical ventilation
Efficacy Study: Number of first episode of LRTI-RSV across 2 RSV seasons	From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 2 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.; Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. LRTI-RSV is defined as an ARI with 3 or more of the lower respiratory signs/symptoms lasting more than 1 day during the same illness, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSA.	Before revaccination and 1, 6, 12 and 18-months after revaccination with placebo in SSA	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
Efficacy Study: Number of first episode of ARI-RSV across 2 RSV seasons	From Day 15 after vaccination until the end of season 2 visit (an average of 12 months of surveillance)	Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated acute respiratory illness (ARI) is assessed. ARI-RSV is defined as an ARI with at least 1 signs/symptoms lasting more than 1 day, plus RT-PCR-confirmed RSV infection within 7 days of ARI symptom onset.
Efficacy Study: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers	Before vaccination, 1-month after vaccination, before season 2 (approximately 12 months after vaccination)	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSA: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSA.	1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSA	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.; Seroresponse rate from before revaccination to 1 month after revaccination.
SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSB	Before revaccination and 1, 6, 12 and 18-months after revaccination with placebo in SSB	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSB: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSB.	1 month after receiving the initial vaccination in the efficacy study and 1 month after revaccination in SSB	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.; Seroresponse rate from before revaccination to 1 month after revaccination.
SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received placebo in SSC.	Participants receiving placebo at the Year 3 and Year 4 vaccination: 1 month and 3, 3.5, 4 and 4.5 years after efficacy study vaccination. Participants receiving placebo at the Year 3 vaccination: 1 month, 3 and 3.5 years after efficacy study vaccination	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.
SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 3)	1 month after receiving the initial vaccination in the efficacy study and before revaccination, and 1, 6, 12 and 18-months after revaccination with RSVpreF in SSC	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.; Seroresponse rate at 1 month after revaccination.
SSC: Respiratory Syncytial Virus Subgroup A (RSV A) and RSV B neutralizing titers from participants who received RSVpreF in SSC (Year 4)	1 month after receiving the initial vaccination in the efficacy study and before revaccination, and 1 and 6-months after revaccination with RSVpreF in SSC	RSV A and RSV B neutralizing titers (NT), expressed as Geometric Mean Titers (GMTs), and geometric mean fold rise (GMFR). The NTs were calculated as the interpolated reciprocal of the serum dilution resulting in 50% reduction in the number of viral focus forming units when compared to the control without test serum.; Seroresponse rate at 1 month after revaccination.

Trial Locations

Locations (275)

St. Vincent's Birmingham (Pharmacy); 🇺🇸 Birmingham, Alabama, United States

St. Vincent's Birmingham; 🇺🇸 Birmingham, Alabama, United States

Medical Affiliated Research Center; 🇺🇸 Huntsville, Alabama, United States

Lenzmeier Family Medicine/CCT Research; 🇺🇸 Glendale, Arizona, United States

Phoenix Clinical LLC; 🇺🇸 Phoenix, Arizona, United States

HOPE Research Institute; 🇺🇸 Tempe, Arizona, United States

The Pain Center of Arizona; 🇺🇸 Phoenix, Arizona, United States

Cognitive Clinical Trials, LLC; 🇺🇸 Phoenix, Arizona, United States

Headlands Research - Scottsdale; 🇺🇸 Scottsdale, Arizona, United States

Alliance for Multispecialty Research, LLC; 🇺🇸 Knoxville, Tennessee, United States

Noble Clinical Research; 🇺🇸 Tucson, Arizona, United States

The Institute for Liver Health dba Arizona Clinical Trials; 🇺🇸 Tucson, Arizona, United States

Hope Clinical Research; 🇺🇸 Canoga Park, California, United States

eStudySite; 🇺🇸 Chula Vista, California, United States

Benchmark Research; 🇺🇸 Fort Worth, Texas, United States

West Coast Research; 🇺🇸 Dublin, California, United States

Marvel Clinical Research 002, LLC; 🇺🇸 Huntington Beach, California, United States

Marvel Clinical Research; 🇺🇸 Huntington Beach, California, United States

Chemidox Clinical Trials; 🇺🇸 Lancaster, California, United States

Ark Clinical Research; 🇺🇸 Long Beach, California, United States

Downtown L.A. Research Center, Inc.; 🇺🇸 Los Angeles, California, United States

Velocity Clinical Research, North Hollywood; 🇺🇸 North Hollywood, California, United States

Clinica mi Salud by Focil Med; 🇺🇸 Oxnard, California, United States

Fomat Medical Research; 🇺🇸 Oxnard, California, United States

De Silva Medical Inc; 🇺🇸 Palmdale, California, United States

Empire Clinical Research; 🇺🇸 Pomona, California, United States

Paradigm Clinical Research Center; 🇺🇸 Redding, California, United States

Artemis Institute for Clinical Research; 🇺🇸 San Diego, California, United States

California Research Foundation; 🇺🇸 San Diego, California, United States

Diablo Clinical Research, Inc.; 🇺🇸 Walnut Creek, California, United States

Lynn Institute of Denver; 🇺🇸 Aurora, Colorado, United States

Tekton Research LLC; 🇺🇸 Longmont, Colorado, United States

Tekton Research, Inc.; 🇺🇸 Beaumont, Texas, United States

Clinical Research Consulting; 🇺🇸 Milford, Connecticut, United States

Stamford Therapeutics Consortium; 🇺🇸 Stamford, Connecticut, United States

JEM Research Institute; 🇺🇸 Atlantis, Florida, United States

IDEAL Clinical Research; 🇺🇸 Pembroke Pines, Florida, United States

Innovative Research of West Florida; 🇺🇸 Clearwater, Florida, United States

Invictus Clinical Research Group, LLC; 🇺🇸 Coconut Creek, Florida, United States

Nature Coast Clinical Research; 🇺🇸 Crystal River, Florida, United States

Universal Axon Clinical Research, LLC (Administrative); 🇺🇸 Doral, Florida, United States

Indago Research & Health Center, Inc; 🇺🇸 Hialeah, Florida, United States

Doral Medical Research, LLC; 🇺🇸 Hialeah, Florida, United States

Wr-Msra.Llc; 🇺🇸 Lake City, Florida, United States

Global Health Research Center, Inc.; 🇺🇸 Miami Lakes, Florida, United States

Optimus U Corporation; 🇺🇸 Miami, Florida, United States

Advance Medical Research Center; 🇺🇸 Miami, Florida, United States

Next Phase Research Alliance; 🇺🇸 Miami, Florida, United States

New Horizon Research Center; 🇺🇸 Miami, Florida, United States

De La Cruz Research Center, LLC; 🇺🇸 Miami, Florida, United States

De La Cruz Research, LLC; 🇺🇸 Miami, Florida, United States

Clinical Site Partners LLC, dba Flourish Research; 🇺🇸 Miami, Florida, United States

Clinical Site Partners, Inc dba CSP Miami; 🇺🇸 Miami, Florida, United States

Headlands Research Orlando; 🇺🇸 Orlando, Florida, United States

Pines Care Research Center, LLC; 🇺🇸 Pembroke Pines, Florida, United States

DBC Research USA; 🇺🇸 Pembroke Pines, Florida, United States

Headlands Research Sarasota; 🇺🇸 Sarasota, Florida, United States

Precision Clinical Research; 🇺🇸 Sunrise, Florida, United States

Clinical Site Partners, Inc; 🇺🇸 Winter Park, Florida, United States

Conquest Research, LLC; 🇺🇸 Winter Park, Florida, United States

Conquest Research; 🇺🇸 Winter Park, Florida, United States

Javara - Privia Medical Group Georgia - Albany; 🇺🇸 Albany, Georgia, United States

Coastal Heritage Clinical Research; 🇺🇸 Hinesville, Georgia, United States

Javara - Privia Medical Group Georgia - Savannah; 🇺🇸 Savannah, Georgia, United States

Javara Inc.; 🇺🇸 Sugar Land, Texas, United States

Privia Medical Group Georgia, LLC; 🇺🇸 Thomasville, Georgia, United States

Velocity Clinical Research, Savannah; 🇺🇸 Savannah, Georgia, United States

Clinical Research Atlanta; 🇺🇸 Stockbridge, Georgia, United States

Snake River Research, PLLC; 🇺🇸 Idaho Falls, Idaho, United States

Solaris Clinical Research; 🇺🇸 Meridian, Idaho, United States

Great Lakes Clinical Trials, LLC dba Flourish Research; 🇺🇸 Chicago, Illinois, United States

Great Lakes Clinical Trials; 🇺🇸 Chicago, Illinois, United States

DM Clinical Research; 🇺🇸 River Forest, Illinois, United States

Affinity Health Corp; 🇺🇸 Oak Brook, Illinois, United States

Accellacare - DuPage; 🇺🇸 Oak Lawn, Illinois, United States

Acellacare - DuPage; 🇺🇸 Oak Lawn, Illinois, United States

MOC Research; 🇺🇸 Mishawaka, Indiana, United States

Velocity Clinical Research Valparaiso; 🇺🇸 Valparaiso, Indiana, United States

University of Iowa Health Care; 🇺🇸 Iowa City, Iowa, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

Meridian Clinical Research, LLC; 🇺🇸 Cincinnati, Ohio, United States

Velocity Clinical Research, Sioux City; 🇺🇸 Sioux City, Iowa, United States

Ochsner Clinic Foundation; 🇺🇸 New Orleans, Louisiana, United States

Ochsner Medical Center - Kenner; 🇺🇸 Kenner, Louisiana, United States

Velocity Clinical Research, Metairie; 🇺🇸 Metairie, Louisiana, United States

Velocity Clinical Research, Rockville; 🇺🇸 Rockville, Maryland, United States

Velocity Clinical Research; 🇺🇸 Rockville, Maryland, United States

ActivMed Practices & Research, LLC; 🇺🇸 Methuen, Massachusetts, United States

University of Massachusetts Chan Medical School; 🇺🇸 Worcester, Massachusetts, United States

Michigan Center of Medical Research (MICHMER); 🇺🇸 Farmington Hills, Michigan, United States

Ascension St. John Hospital Vaccine Research Unit; 🇺🇸 Grosse Pointe Woods, Michigan, United States

Oakland Medical Research; 🇺🇸 Troy, Michigan, United States

Arcturus Healthcare , PLC, Troy Internal Medicine Research Division; 🇺🇸 Troy, Michigan, United States

Saint Louis University; 🇺🇸 Saint Louis, Missouri, United States

Sundance Clinical Research; 🇺🇸 Saint Louis, Missouri, United States

Skyline Medical Center, PC/CCT Research; 🇺🇸 Elkhorn, Nebraska, United States

Quality Clinical Research; 🇺🇸 Omaha, Nebraska, United States

Wr-Crcn, Llc.; 🇺🇸 Las Vegas, Nevada, United States

Las Vegas Clinical Trials; 🇺🇸 North Las Vegas, Nevada, United States

ActivMed Practices and Research, LLC.; 🇺🇸 Portsmouth, New Hampshire, United States

IMA Clinical Research; 🇺🇸 Raritan, New Jersey, United States

South Jersey Infectious Disease; 🇺🇸 Somers Point, New Jersey, United States

IMA Clinical Research Warren; 🇺🇸 Warren, New Jersey, United States

CHEAR Center LLC; 🇺🇸 Bronx, New York, United States

Drug Trials America; 🇺🇸 Hartsdale, New York, United States

Corning Center for Clinical Research; 🇺🇸 Horseheads, New York, United States

Rochester Clinical Research, Inc.; 🇺🇸 Rochester, New York, United States

Rochester Clinical Research, LLC; 🇺🇸 Rochester, New York, United States

University of Rochester Medical Center; 🇺🇸 Rochester, New York, United States

Velocity Clinical Research, Vestal; 🇺🇸 Vestal, New York, United States

Atrium Health - Strive Vaccine Research Clinic; 🇺🇸 Charlotte, North Carolina, United States

Accellacare - Charlotte; 🇺🇸 Charlotte, North Carolina, United States

Tryon Medical Partners, PLLC; 🇺🇸 Charlotte, North Carolina, United States

Sensenbrenner Primary Care Research Office; 🇺🇸 Charlotte, North Carolina, United States

Accellacare - Wilmington - 1917 Tradd Court; 🇺🇸 Wilmington, North Carolina, United States

Accellacare - Wilmington; 🇺🇸 Wilmington, North Carolina, United States

Wake Forest University Health Sciences; 🇺🇸 Winston-Salem, North Carolina, United States

Meridian Clinical Research; 🇺🇸 Cincinnati, Ohio, United States

Velocity Clinical Research, Mt. Auburn; 🇺🇸 Cincinnati, Ohio, United States

Velocity Clinical Research - Cincinnati; 🇺🇸 Cincinnati, Ohio, United States

Velocity Clinical Research, Springdale; 🇺🇸 Cincinnati, Ohio, United States

Centricity Research Columbus Ohio Multispecialty; 🇺🇸 Columbus, Ohio, United States

Tekton Research, Inc; 🇺🇸 Yukon, Oklahoma, United States

Tekton Research, LLC.; 🇺🇸 Beaumont, Texas, United States

The Corvallis Clinic, PC; 🇺🇸 Corvallis, Oregon, United States

Velocity Clinical Research, Grants Pass; 🇺🇸 Grants Pass, Oregon, United States

Velocity Clinical Research, Medford; 🇺🇸 Medford, Oregon, United States

Summit Headlands, LLC; 🇺🇸 Portland, Oregon, United States

Kaiser Permanente Northwest-Center for Health Research; 🇺🇸 Portland, Oregon, United States

Capital Area Research, LLC; 🇺🇸 Camp Hill, Pennsylvania, United States

Central Erie Primary Care; 🇺🇸 Erie, Pennsylvania, United States

West Shore Family Practice, P. C.; 🇺🇸 Mechanicsburg, Pennsylvania, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Penn Prevention Unit; 🇺🇸 Philadelphia, Pennsylvania, United States

Velocity Clinical Research, Providence; 🇺🇸 East Greenwich, Rhode Island, United States

Accellacare US Inc., d/b/a Accellacare of Knoxville; 🇺🇸 Knoxville, Tennessee, United States

Clinical Research Associates, Inc.; 🇺🇸 Nashville, Tennessee, United States

Innovo Research - Austin Regional Clinic; 🇺🇸 Austin, Texas, United States

Privia Medical Group Gulf Coast, PLLC; 🇺🇸 Sugar Land, Texas, United States

North Texas Infectious Diseases Consultants, P.A; 🇺🇸 Dallas, Texas, United States

Texas Health Family Care; 🇺🇸 Fort Worth, Texas, United States

Allure Health at Mt. Olympus Medical Research; 🇺🇸 Friendswood, Texas, United States

Hany H. Ahmed, MD; 🇺🇸 Houston, Texas, United States

Helios Clinical Research - HOU; 🇺🇸 Houston, Texas, United States

HG Pediatrics; 🇺🇸 Houston, Texas, United States

Trio Clinical Trials, LLC; 🇺🇸 Houston, Texas, United States

Van Tran Family Practice; 🇺🇸 Houston, Texas, United States

Ventavia Research Group, LLC; 🇺🇸 Houston, Texas, United States

Centex Studies; 🇺🇸 Houston, Texas, United States

DM Clinical Research - Cy Fair; 🇺🇸 Houston, Texas, United States

DM Clinical Research ? CyFair; 🇺🇸 Houston, Texas, United States

DM Clinical Research - Bellaire; 🇺🇸 Houston, Texas, United States

Texas Center for Drug Development, Inc.; 🇺🇸 Houston, Texas, United States

DM Clinical Research - Humble; 🇺🇸 Humble, Texas, United States

DM Clinical Research - MDC; 🇺🇸 Humble, Texas, United States

Milton Haber, M.D.; 🇺🇸 Laredo, Texas, United States

Milton Haber, MD; 🇺🇸 Laredo, Texas, United States

SMS Clinical Research; 🇺🇸 Mesquite, Texas, United States

Sun Research Institute; 🇺🇸 San Antonio, Texas, United States

Clinical Trials of Texas, LLC dba Flourish Research; 🇺🇸 San Antonio, Texas, United States

Clinical Trials of Texas, LLC; 🇺🇸 San Antonio, Texas, United States

Dynamed Clinical Research, LP d/b/a DM Clinical Research; 🇺🇸 Sugar Land, Texas, United States

Mt Olympus Medical Research; 🇺🇸 Sugar Land, Texas, United States

DM Clinical Research, Martin Diagnostic Clinic; 🇺🇸 Tomball, Texas, United States

Martin Diagnostic Clinic; 🇺🇸 Tomball, Texas, United States

J. Lewis Research Inc. / Foothill Family Clinic Draper; 🇺🇸 Draper, Utah, United States

J. Lewis Research, Inc. / Foothill Family Clinic Draper; 🇺🇸 Draper, Utah, United States

Tanner Clinic; 🇺🇸 Layton, Utah, United States

J. Lewis Research, Inc. / Jordan River Family Medicine; 🇺🇸 South Jordan, Utah, United States

Velocity Clinical Research, Salt Lake City; 🇺🇸 West Jordan, Utah, United States

Centricity Research Suffolk Primary Care; 🇺🇸 Suffolk, Virginia, United States

Suffolk Multispecialty Research; 🇺🇸 Suffolk, Virginia, United States

Virginia Gastroenterology Clinical Research; 🇺🇸 Suffolk, Virginia, United States

Northwest Clinical Research Center; 🇺🇸 Bellevue, Washington, United States

Sound Medical Research; 🇺🇸 Port Orchard, Washington, United States

MultiCare Institute for Research & Innovation; 🇺🇸 Tacoma, Washington, United States

MultiCare Medical Group; 🇺🇸 Tacoma, Washington, United States

Central Washington Health Services Association d/b/a Confluence Health; 🇺🇸 Wenatchee, Washington, United States

Research Building; 🇺🇸 Wenatchee, Washington, United States

Wenatchee Valley Hospital; 🇺🇸 Wenatchee, Washington, United States

Allegiance Research Specialists, LLC; 🇺🇸 Wauwatosa, Wisconsin, United States

Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich; 🇦🇷 Caba, Buenos Aires, Argentina

Fundación Respirar; 🇦🇷 Caba, Buenos Aires, Argentina

Clinica Privada Instituto Medico Platense S.A.; 🇦🇷 La Plata, Buenos Aires, Argentina

Instituto De Investigaciones Clínicas Mar Del Plata; 🇦🇷 Mar del Plata, Buenos Aires, Argentina

Clinica Mayo de Urgencias Medicas Cruz Blanca S.R.L; 🇦🇷 San Miguel de Tucuman, Tucuman, Argentina

Hospital de Clinicas Presidente Nicolas Avellaneda; 🇦🇷 San Miguel de Tucuman, Tucuman, Argentina

Clinica Privada del Sol S.A.; 🇦🇷 Cordoba, Argentina

IMAC - Instituto Medico de Alta Complejidad; 🇦🇷 Salta, Argentina

Kaye Edmonton Clinic; 🇨🇦 Edmonton, Alberta, Canada

Stollery Children's Hospital; 🇨🇦 Edmonton, Alberta, Canada

University Of Alberta Hospital; 🇨🇦 Edmonton, Alberta, Canada

Aggarwal and Associates Limited; 🇨🇦 Brampton, Ontario, Canada

Dawson Clinical Research Inc.; 🇨🇦 Guelph, Ontario, Canada

Dawson Clinical Research Inc; 🇨🇦 Guelph, Ontario, Canada

Premier Clinical Trial Network; 🇨🇦 Hamilton, Ontario, Canada

Hamilton Medical Research Group; 🇨🇦 Hamilton, Ontario, Canada

Centricity Research Toronto LMC Multispecialty; 🇨🇦 Toronto, Ontario, Canada

LMC Clinical Research Inc. (Clinical Pharmacology Unit); 🇨🇦 Toronto, Ontario, Canada

Dr. Anil K. Gupta Medicine Professional Corporation; 🇨🇦 Toronto, Ontario, Canada

Centricity Research Toronto Manna Multispecialty; 🇨🇦 Toronto, Ontario, Canada

Manna Research (Toronto); 🇨🇦 Toronto, Ontario, Canada

Diex Recherche Joliette Inc; 🇨🇦 Quebec, Canada

Centricity Research Mirabel Multispecialty; 🇨🇦 Mirabel, Quebec, Canada

Clinique de Médecine Urbaine du Quartier Latin; 🇨🇦 Montreal, Quebec, Canada

Alpha Recherche Clinique; 🇨🇦 Québec, Quebec, Canada

Diex Recherche Sherbrooke Inc.; 🇨🇦 Sherbrooke, Quebec, Canada

Diex Recherche Joliette Inc.; 🇨🇦 St-Charles-Borromee, Quebec, Canada

Diex Recherche Victoriaville Inc.; 🇨🇦 Victoriaville, Quebec, Canada

Diex Recherche Quebec Inc.; 🇨🇦 Quebec, Canada

Centre de Recherche Saint-Louis; 🇨🇦 Quebec, Canada

Espoo Vaccine Research Clinic; 🇫🇮 Espoo, Finland

FVR, Etelä-Helsingin rokotetutkimusklinikka; 🇫🇮 Helsinki, Finland

Helsinki East Vaccine Research Clinic; 🇫🇮 Helsinki, Finland

Terveystalo Jyväskylä; 🇫🇮 Jyväskylä, Finland

Järvenpää Vaccine Research Clinic; 🇫🇮 Järvenpää, Finland

Kokkola Vaccine Research Clinic; 🇫🇮 Kokkola, Finland

Oulu Vaccine Research Clinic; 🇫🇮 Oulu, Finland

Pori Vaccine Research Clinic; 🇫🇮 Pori, Finland

Seinäjoki Vaccine Research Clinic; 🇫🇮 Seinajoki, Finland

Tampere Vaccine Research Clinic; 🇫🇮 Tampere, Finland

Terveystalo Tampere; 🇫🇮 Tampere, Finland

Terveystalo Turku Pulssi; 🇫🇮 Turku, Finland

Turku Vaccine Research Clinic; 🇫🇮 Turku, Finland

Tenjin General Clinic; 🇯🇵 Fukuoka-shi, Fukuoka, Japan

Seishinkai Inoue Hospital; 🇯🇵 Itoshima, Fukuoka, Japan

Sasaki Clinic; 🇯🇵 Amagasaki, Hyōgo, Japan

Motomachi Takatsuka Naika Clinic; 🇯🇵 Yokohama, Kanagawa, Japan

Medical Corporation Heishinkai OPHAC Hospital; 🇯🇵 Osaka-shi, Osaka, Japan

Sugiura Clinic; 🇯🇵 Kawaguchi, Saitama, Japan

Nihonbashi Sakura Clinic; 🇯🇵 Chuo-ku, Tokyo, Japan

Tokyo Eki Center Building Clinic; 🇯🇵 Chuo-ku, Tokyo, Japan

Fukuwa Clinic; 🇯🇵 Chuo-ku, Tokyo, Japan

Tokyo Asbo Clinic; 🇯🇵 Chuo-ku, Tokyo, Japan

Medical Corp. Seikoukai New Medical Research System Clinic; 🇯🇵 Hachioji-shi, Tokyo, Japan

Hillside Clinic Jingumae; 🇯🇵 Shibuya-ku, Tokyo, Japan

Clinical Research Hospital Tokyo; 🇯🇵 Shinjuku-ku, Tokyo, Japan

Oda Clinic; 🇯🇵 Shinjuku-ku, Tokyo, Japan

Souseikai Sumida Hospital; 🇯🇵 Sumida-ku, Tokyo, Japan

Sekino Hospital; 🇯🇵 Toshima-ku, Tokyo, Japan

SOUSEIKAI PS Clinic; 🇯🇵 Fukuoka, Japan

AMC Nishiumeda Clinic; 🇯🇵 Osaka, Japan

Meander Medisch Centrum; 🇳🇱 Amersfoort, Netherlands

PoliDirect Amsterdam West; 🇳🇱 Amsterdam, Netherlands

Huisartsencentrum Parklaan; 🇳🇱 Eindhoven, Netherlands

Huisartsenpraktijk Radesingel; 🇳🇱 Groningen, Netherlands

Gezondheidscentrum Leonardus; 🇳🇱 Helmond, Netherlands

Spaarne Gasthuis; 🇳🇱 Hoofddorp, Netherlands

PoliDirect Nieuwegein; 🇳🇱 Nieuwegein, Netherlands

Franciscus Gasthuis & Vlietland, location Gasthuis; 🇳🇱 Rotterdam, Netherlands

Huisartsen Soest; 🇳🇱 Soest, Netherlands

UMC Utrecht; 🇳🇱 Utrecht, Netherlands

Julius Clinical Breda; 🇳🇱 Zeist, Netherlands

Josha Research; 🇿🇦 Bloemfontein, FREE State, South Africa

Welkom Clinical Trial Centre (MERC WELKOM); 🇿🇦 Welkom, FREE State, South Africa

Worthwhile Clinical Trials; 🇿🇦 Benoni, Gauteng, South Africa

MERC Research (Pty) Ltd - Kempton; 🇿🇦 Kempton Park, Gauteng, South Africa

MERCLINCO (Pty) Ltd - Kempton; 🇿🇦 Kempton Park, Gauteng, South Africa

Dr A Jacovides & Partners Inc.; 🇿🇦 Midrand, Gauteng, South Africa

Newtown Clinical Research Centre (PTY) LTD; 🇿🇦 Newtown, Gauteng, South Africa

Emmed Research; 🇿🇦 Pretoria, South Africa

Global Clinical Trials; 🇿🇦 Pretoria, Gauteng, South Africa

About Allergy; 🇿🇦 Pretoria, Gauteng, South Africa

Into Research; 🇿🇦 Pretoria, Gauteng, South Africa

Jongaie Research; 🇿🇦 Pretoria, Gauteng, South Africa

Synexus SA- Watermeyer Clinical Research Center; 🇿🇦 Pretoria, Gauteng, South Africa

Setshaba Research Centre; 🇿🇦 Soshanguve, Gauteng, South Africa

Wits Vaccines & Infectious Diseases Analytics; 🇿🇦 Soweto, Gauteng, South Africa

FCRN Clinical Trial Centre; 🇿🇦 Vereeniging, Gauteng, South Africa

MERC Research (Pty) Ltd - Middelburg; 🇿🇦 Middelburg, Mpumalanga, South Africa

Synexus - Helderberg Clinical Research Centre - Somerset West; 🇿🇦 Cape Town, Western CAPE, South Africa

TREAD Research; 🇿🇦 Cape Town, Western CAPE, South Africa

Be Part Yoluntu Centre; 🇿🇦 Paarl, Western CAPE, South Africa

Helderberg Clinical Trials Centre; 🇿🇦 Somerset West, Western CAPE, South Africa

Botho Ke Bontle Health Services; 🇿🇦 Pretoria, South Africa